Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Glencore's ASX Listing Could be Precursor to New Rio Tie-Up Attempt -- Market Talk

Glencore's ASX Listing Could be Precursor to New Rio Tie-Up Attempt -- Market Talk

Dow JonesDow Jones2026/09/28 14:02

1402 GMT - Glencore is set to benefit from its upcoming listing on the Australian stock exchange on Oct. 14, RBC Capital Markets analyst Ben Davis writes. "The listing is intended to improve Glencore's profile with Australian investors, broaden its shareholder base, improve trading liquidity and enhance corporate financial flexibility," the analyst says. Davis adds the move could also be a precursor to another merger attempt with Rio Tinto after the failed tie-up in February. RBC has an outperform rating on the stock and a 660 pence price target. Shares are down 1.4% at 553.20 pence. (joseph.wilkins@wsj.com)

(END) Dow Jones Newswires

September 28, 2026 10:02 ET (14:02 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss